Clinical, endoscopic and radiographic outcomes with ustekinumab in medically‐refractory Crohn's disease: real world experience from a multicentre cohort
Alimentary Pharmacology & Therapeutics2017Vol. 45(9), pp. 1232–1243
Citations Over TimeTop 1% of 2017 papers
Christopher Ma, Richard N. Fedorak, Gilaad G. Kaplan, Levinus A. Dieleman, Shane Devlin, N Stern, Karen I. Kroeker, Cynthia H. Seow, Yvette Leung, Kerri L. Novak, Brendan P. Halloran, Vivian Huang, Karen Wong, Philip K. Blustein, Subrata Ghosh, Remo Panaccione
Abstract
Ustekinumab is an effective therapeutic option for inducing and maintaining clinical, endoscopic and radiographic response in patients with Crohn's disease failing anti-TNF therapy.
Related Papers
- Profile of ustekinumab and its potential in patients with moderate-to-severe Crohn's disease(2014)
- → Ustekinumab: a novel therapeutic option in Crohn’s disease(2016)10 cited
- → 985 EFFICACY OF MIRIKIZUMAB IN COMPARISON TO USTEKINUMAB IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE: RESULTS FROM THE PHASE 3 VIVID 1 STUDY(2024)2 cited
- → EP1276: USTEKINUMAB HAS COMPARABLE LONG-TERM EFFECTIVENESS AS ANTI-TNF AGENTS IN BIOLOGIC-NAÏVE PATIENTS WITH CROHN'S DISEASE(2022)
- → Su1713 IMPACT OF IMMEDIATE OPTIMIZATION OF USTEKINUMAB ON MEDIUM TERM TARGETS IN SEVERE CROHN'S DISEASE: THE MUST STUDY(2023)